A global approach to HIV-1 vaccine development.

Stephenson KE, Barouch DH. A global approach to HIV-1 vaccine development. Immunol Rev. 2013 Jul;254(1):295-304. doi: 10.1111/imr.12073. Review. PubMed PMID: 23772627; PubMed Central PMCID: PMC3693768.

Comparative characterization of transfection- and infection-derived simian immunodeficiency virus challenge stocks for in vivo nonhuman primate studies.

Del Prete GQ, Scarlotta M, Newman L, Reid C, Parodi LM, Roser JD, Oswald K, Marx PA, Miller CJ, Desrosiers RC, Barouch DH, Pal R, Piatak M Jr, Chertova E, Giavedoni LD, O’Connor DH, Lifson JD, Keele BF. Comparative characterization of transfection- and infection-derived simian immunodeficiency virus challenge stocks for in vivo nonhuman primate studies. J. Virol. 2013; 87:4584-4595.

Location and dynamics of the immunodominant CD8 T cell response to SIVDnef immunization and SIVmac251 vaginal challenge.

Sasikala-Appukuttan, A. K., Kim, H. O., Kinzel N. J., Hong, J. J., Smith, A. J., Wagstaff, R., Reilly, C., Piatak, M., Lifson, J. D., Reeves, R. K., Johnson R. P., Haase, A. T., and Skinner, P. J. 2013. Location and dynamics of the immunodominant CD8 T cell response to SIVDnef immunization and SIVmac251 vaginal challenge. PLoS One 8(12):e81623. PMID: 24349100. PMCID: PMC3857218

The effects of somatic hypermutation on neutralizing and binding in the PGT121 family of broadly neutralizing antibodies.

Sok D, Laserson U, Laserson J, Liu Y, Vigneault F, Julien JP, Briney B, Ramos A, Saye KF, Le K, Mahan A, Wang S, Kardar M, Yaari G, Walker LM, Simen BB, St John EP, Chan-Hui PY, Swiderek K, Kleinstein SH, Alter G, Seaman MS, Chakraborty AK, Koller D, Wilson IA, Church GM, Burton DR, Poignard P. The effects of somatic hypermutation on neutralizing and binding in the PGT121 family of broadly neutralizing antibodies. PLoS Pathog. 2013, 9(11):e1003754.

A gp41 MPER-specific llama VHH requires a hydrophobic CDR3 for neutralization but not for antigen recognition.

Hulsik DL, Liu YY, Strokappe NM, Battella S, El Khattabi M, McCoy LE, Sabin C, Hinz A, Hock M, Macheboeuf P, Bonvin AM, Langedijk JP, Davis D, Forsman-Quigley A, Aasa-Chapman MM, Seaman MS, Ramos A, Poignard P, Favier A, Simorre JP, Weiss RA, Verrips CT, Rutten L. A gp41 MPER-specific llama VHH requires a hydrophobic CDR3 for neutralization but not for antigen recognition. PLos Path. 2013, 9(3):e1003202.

Computational prediction of broadly neutralizing HIV-1 antibody epitopes from neutralization activity data.

Ferguson AL, Falkowska E, Walker LM, Seaman MS, Burton DR, Chakraborty AK. Computational prediction of broadly neutralizing HIV-1 antibody epitopes from neutralization activity data. PLoS One. 2013, 8(12):e80562.

Loss of bone marrow NK cells during SIV infection is associated with increased turnover rates and cytotoxicity but not changes in trafficking.

Li, H., Evans, T. I., and Reeves R. K. 2013. Loss of bone marrow NK cells during SIV infection is associated with increased turnover rates and cytotoxicity but not changes in trafficking. J. Med. Primatol. 42(5):230-236. PMID: 23898936. PMCID: PMC3777546

The production, characterization and application of monoclonal antibodies generated by immunization with HIV-1C clade RGP140 envelope protein.

Hassall M, Page M, Robinson M, Jeffs S, Jones I, Chen H, Seaman MS, Ferguson D, Almond N. The production, characterization and application of monoclonal antibodies generated by immunization with HIV-1C clade RGP140 envelope protein. J. Virol. Methods. 2013, 194(1-2):89-93.

A novel rabbit monoclonal antibody platform to dissect the diverse repertoire of antibody epitopes for HIV-1 Env immunogen design.

Chen Y, Vaine M, Wallace A, Han D, Wan S, Seaman MS, Montefiori D, Wang S, Lu S. A novel rabbit monoclonal antibody platform to dissect the diverse repertoire of antibody epitopes for HIV-1 Env immunogen design. J. Virol. 2013, 87(18):10232-43.

Cross-neutralizing activity of human anti-V3 monoclonal antibodies derived from non-clade B HIV-1 infected individuals.

Andrabi R, Williams C, Wang XH, Li L, Choudhary AK, Wig N, Biswas A, Luthra K, Nadas A, Seaman MS, Nyambi P, Zolla Pazner S, Gorny MK. Cross-neutralizing activity of human anti-V3 monoclonal antibodies derived from non-clade B HIV-1 infected individuals. Virology. 2013, 439(2): 81-8.